Photo of David G. Nathan,  MD

David G. Nathan, MD

Dana-Farber Cancer Institute

Dana-Farber Cancer Institute
Phone: (617) 632-2155
Fax: (617) 632-2161


david_nathan@dfci.harvard.edu

David G. Nathan, MD

Dana-Farber Cancer Institute

EDUCATIONAL TITLES

  • Robert A Stranahan Distinguished Professor of Peds, Pediatrics, Harvard Medical School

Research Abstract

The pathophysiology and treatment of congential bone marrow failure and red cell syndromes.

Publications

Powered by Harvard Catalyst
  • Sankaran VG, Ghazvinian R, Do R, Thiru P, Vergilio JA, Beggs AH, Sieff CA, Orkin SH, Nathan DG, Lander ES, Gazda HT. Exome sequencing identifies GATA1 mutations resulting in Diamond-Blackfan anemia. J Clin Invest 2012; 122:2439-43. PubMed
  • Narla A, Vlachos A, Nathan DG. Diamond blackfan anemia treatment: past, present, and future. Semin Hematol 2011; 48:117-23. PubMed
  • Field JJ, Nathan DG, Linden J. Targeting iNKT cells for the treatment of sickle cell disease. Clin Immunol 2011. PubMed
  • Sankaran VG, Nathan DG. Reversing the hemoglobin switch. N Engl J Med 2010; 363:2258-60. PubMed
  • Sankaran VG, Nathan DG. Thalassemia: an overview of 50 years of clinical research. Hematol Oncol Clin North Am 2010; 24:1005-20. PubMed
  • Nathan DG. A life-long quest to understand and treat genetic blood disorders. Cell 2010; 143:17-20. PubMed
  • Bunn HF, Nathan DG, Dover GJ, Hebbel RP, Platt OS, Rosse WF, Ware RE. Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood 2010; 116:687-92. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: Hepatitis C. Genome Med 2010; 2:4. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: Crohn's disease. Genome Med 2010; 1:103. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: cholesterol and coronary artery disease. Genome Med 2009; 1:60. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: the Obama effect redux. Genome Med 2009; 1:86. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: enzyme-replacement therapy of the lysosomal storage diseases. Genome Med 2010; 1:114. PubMed
  • Nathan DG, Orkin SH. Musings on genome medicine: the slow but inexorable process of medical care reform in the United States. Genome Med 2009; 1:94. PubMed
  • Rebel VI, Tanaka M, Lee JS, Hartnett S, Pulsipher M, Nathan DG, Mulligan RC, Sieff CA. One-day ex vivo culture allows effective gene transfer into human nonobese diabetic/severe combined immune-deficient repopulating cells using high-titer vesicular stomatitis virus G protein pseudotyped retrovirus. Blood 1999; 93:2217-24. PubMed
  • Nathan DG, Weatherall DJ. Iron chelation with oral deferiprone in patients with thalassemia. N Engl J Med 1998; 339:1711-2; author reply 1713. PubMed
  • Janov AJ, Leong T, Nathan DG, Guinan EC. Diamond-Blackfan anemia. Natural history and sequelae of treatment. Medicine (Baltimore) 1996; 75:77-8. PubMed
  • Olivieri NF, Nathan DG, MacMillan JH, Wayne AS, Liu PP, McGee A, Martin M, Koren G, Cohen AR. Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 1994; 331:574-8. PubMed
  • Guinan EC, Lopez KD, Huhn RD, Felser JM, Nathan DG. Evaluation of granulocyte-macrophage colony-stimulating factor for treatment of pancytopenia in children with fanconi anemia. J Pediatr 1994; 124:144-50. PubMed
  • Bianchi DW, Bernfield M, Nathan DG. A revived opportunity for fetal research. Nature 1993; 363:12. PubMed
  • Guinan EC, Lee YS, Lopez KD, Kohler S, Oette DH, Bruno E, Kozakewich H, Nathan DG, Hoffman R. Effects of interleukin-3 and granulocyte-macrophage colony-stimulating factor on thrombopoiesis in congenital amegakaryocytic thrombocytopenia. Blood 1993; 81:1691-8. PubMed
  • Wayne AS, Kevy SV, Nathan DG. Transfusion management of sickle cell disease. Blood 1993; 81:1109-23. PubMed
  • Davies K, TePas EC, Nathan DG, Mathey-Prevot B. Interleukin-3 expression by activated T cells involves an inducible, T-cell-specific factor and an octamer binding protein. Blood 1993; 81:928-34. PubMed
  • Jubinsky PT, Nathan DG, Wilson DJ, Sieff CA. A low-affinity human granulocyte-macrophage colony-stimulating factor/murine erythropoietin hybrid receptor functions in murine cell lines. Blood 1993; 81:587-91. PubMed
  • Sieff CA, Yokoyama CT, Zsebo KM, Trammell J, Andersen JW, Nathan DG, Williams DA. The production of steel factor mRNA in Diamond-Blackfan anaemia long-term cultures and interactions of steel factor with erythropoietin and interleukin-3. Br J Haematol 1992; 82:640-7. PubMed
  • McDonagh KT, Dover GJ, Donahue RE, Nathan DG, Agricola B, Byrne E, Nienhuis AW. Hydroxyurea-induced HbF production in anemic primates: augmentation by erythropoietin, hematopoietic growth factors, and sodium butyrate. Exp Hematol 1992; 20:1156-64. PubMed
  • Liboi E, Jubinsky P, Andrews NC, Nathan DG, Mathey-Prevot B. Enhanced expression of interleukin-3 and granulocyte-macrophage colony-stimulating factor receptor subunits in murine hematopoietic cells stimulated with hematopoietic growth factors. Blood 1992; 80:1183-9. PubMed
  • Crosier KE, Wong GG, Mathey-Prevot B, Nathan DG, Sieff CA. A functional isoform of the human granulocyte/macrophage colony-stimulating factor receptor has an unusual cytoplasmic domain. Proc Natl Acad Sci U S A 1991; 88:7744-8. PubMed
Hide